PubMed Health⌕ Search

Biomedical subjects

A Anumonye

Publications and source records attributed to A Anumonye.

15 recordsLinked to original sources
PubMed1980

Drug use among young people in Lagos, Nigeria.

This paper presents the results of two studies on drug abuse carried out among young people. One study included a sample of 2,846 pupils from 17 secondary schools in Lagos, the other 300 patients admitted to the Lagos University Teaching Hospital for treatment of drug abuse. Among the secondary school students the major substances used were alcohol, barbiturates, central nervous system stimulants, tobacco, Mandrax and cannabis. The majority of hospital patients treated for drug abuse were cannabis users.

Adolescent↗
PubMed1976

Clinical trial of pimozide.

Pimozide and Chlorpromazine were compared in chronic schizophrenics for their therapeutic effectiveness and tolerance, for four-weeks in both cases and for twelve months for pimozide. The minimum and maximum doses were 1 mg to 4 mg single dose for pimozide and 100 to 200 mg thrice daily for chlorpromazine. No significant global differences between the range of therapeutic activity of the two regimens were observed. Slightly more improvement was observed in mood and motor activity with pimozide. Drowsiness and dizziness, and extrapyramidal effects were more prominent with clorpromazine. Other side effects were infrequent. A prolonged improvement in 8 pimozide patients was maintained with mainly weight gain. The advantages of pimozide in chronic unsocialized schizophrenics appear to rest on its single oral daily dose regime, minimal undersirable effects, its specific enhancement of social integration and absence of undersirable effect on mental and physical performance.

Adolescent↗
PubMed1975

Treatment of 'brain fag' syndrome.

Sixty male Nigerian students suffering from 'brain fag' syndrome who had failed to respond satisfactorily to 4 to 8 weeks' treatment with other benzodiazepines were treated with 1 to 2 mg. lorazepam t.i.d. There was marked improvement in symptoms in over 80% of the patients by the end of the second week of lorazepam treatment. Side-effects were considerably less frequent or incapacitating than with the previous therapy.

Adolescent↗